Fig. 3From: Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspectiveMedian blood Tyr levels of 11 patients with PKU taking L-AA versus CGMP-AA (last ANSE) with different percentages of contribution to the total protein substitute. CGMP-AA, casein glycomacropeptide supplements; L-AA, phenylalanine-free L-amino acid supplements; Tyr, tyrosine. The number below each pair of bars represents Patient IDBack to article page